Patient cohort
| . | Data . |
|---|---|
| Patients | 73 (100) |
| Adult cases | 48 (65.8) |
| Elderly (≥60 y) | 25 (34.2) |
| Adult (40-59 y) | 17 (23.3) |
| Young adult (19-39 y) | 6 (8.2) |
| Pediatric cases | 25 (34.2) |
| Adolescent (15-18 y) | 3 (4.1) |
| Child (3-14 y) | 15 (20.5) |
| Infant (<3 y) | 7 (9.6) |
| Sex, female | 38 (52.1) |
| Background | |
| De novo AML | 66 (90.4) |
| Potential t-AML | 3 (4.0) |
| MDS-AML | 2 (2.7) |
| t-MDS-AML | 2 (2.7) |
| Tumor samples | 138 (100) |
| Diagnosis samples | 52 (37.7) |
| Relapse samples | 80 (58.0) |
| R1 and R1-P | 60 (43.5) |
| R2 and R2-P | 16 (11.6) |
| R3 | 4 (2.9) |
| Primary resistant samples | 6 (4.3) |
| Matched normal controls | 61 (100) |
| BMS cells | 43 (70.5) |
| Complete remission samples | 17 (27.9) |
| BMS/complete remission cell combination | 1 (1.6) |
| Average age at onset, y | |
| Adult cases | 59.3 (range, 20.5-83.1; median, 61.7) |
| Pediatric cases | 8.2 (range, 0.4-18.2; median, 7.7) |
| Average length of EFS, d (D>R1) | |
| Adult relapse cases | 624 (range, 34-5958; median, 306) |
| Pediatric relapse cases | 365 (range, 69-1110; median, 312.5) |
| Average WBC | |
| Adult cases* | 100 (range, 1-395; median, 80) |
| Pediatric cases | 104 (range, 11-232; median, 50) |
| NK-AML | |
| Adult cases† | 21 (46.7) |
| Pediatric cases | 7 (28.0) |
| Sample purity | 86% (>80% tumor cells; range, 41-100) |
| Cell viability‡ | 61% (≥75% viable cells; range, 6-94) |
| Sampling duration | 1995 through 2016 |
| . | Data . |
|---|---|
| Patients | 73 (100) |
| Adult cases | 48 (65.8) |
| Elderly (≥60 y) | 25 (34.2) |
| Adult (40-59 y) | 17 (23.3) |
| Young adult (19-39 y) | 6 (8.2) |
| Pediatric cases | 25 (34.2) |
| Adolescent (15-18 y) | 3 (4.1) |
| Child (3-14 y) | 15 (20.5) |
| Infant (<3 y) | 7 (9.6) |
| Sex, female | 38 (52.1) |
| Background | |
| De novo AML | 66 (90.4) |
| Potential t-AML | 3 (4.0) |
| MDS-AML | 2 (2.7) |
| t-MDS-AML | 2 (2.7) |
| Tumor samples | 138 (100) |
| Diagnosis samples | 52 (37.7) |
| Relapse samples | 80 (58.0) |
| R1 and R1-P | 60 (43.5) |
| R2 and R2-P | 16 (11.6) |
| R3 | 4 (2.9) |
| Primary resistant samples | 6 (4.3) |
| Matched normal controls | 61 (100) |
| BMS cells | 43 (70.5) |
| Complete remission samples | 17 (27.9) |
| BMS/complete remission cell combination | 1 (1.6) |
| Average age at onset, y | |
| Adult cases | 59.3 (range, 20.5-83.1; median, 61.7) |
| Pediatric cases | 8.2 (range, 0.4-18.2; median, 7.7) |
| Average length of EFS, d (D>R1) | |
| Adult relapse cases | 624 (range, 34-5958; median, 306) |
| Pediatric relapse cases | 365 (range, 69-1110; median, 312.5) |
| Average WBC | |
| Adult cases* | 100 (range, 1-395; median, 80) |
| Pediatric cases | 104 (range, 11-232; median, 50) |
| NK-AML | |
| Adult cases† | 21 (46.7) |
| Pediatric cases | 7 (28.0) |
| Sample purity | 86% (>80% tumor cells; range, 41-100) |
| Cell viability‡ | 61% (≥75% viable cells; range, 6-94) |
| Sampling duration | 1995 through 2016 |
Data are number of patients (% of total group), unless otherwise stated. Detailed biological and clinical data for each patient/sample are presented in supplemental Tables 2 and 3.
BMS, bone marrow–derived stromal cells; D, diagnosis; NK-AML, normal karyotype AML at diagnosis; R1/2/3, sequential relapses; R1/2-P, persistent relapse specimen; t-AML, treatment related AML; WBC, white blood cell count (at diagnosis).
Information lacking for 6 adults.
Information lacking for 3 adults.
Accounts only for cryopreserved cells.